Autologous CD7-directed chimeric antigen receptor (CAR) T-cell therapy in which patient T cells are genetically engineered to express a CAR targeting CD7, enabling TCR-independent activation and cytotoxic killing of CD7-positive T/NK-cell malignancies.
Autologous T cells are genetically engineered to express a chimeric antigen receptor targeting CD7. Upon binding CD7 on malignant T/NK cells, the CAR triggers TCR-independent activation and cytotoxic killing via perforin/granzyme release and cytokine-mediated effects, leading to elimination of CD7-positive tumor cells.
YES
DIRECT
Anti-CD7 CAR-T cells bind CD7 on target cells, become activated, and kill via perforin/granzyme-mediated cytolysis (and death receptor/cytokine-dependent apoptosis).
Monoclonal IgG1 anti-HER2 antibody that binds the extracellular domain of HER2, inhibits HER2 signaling, and mediates antibody-dependent cellular cytotoxicity (ADCC).
Humanized IgG1 monoclonal antibody targeting the extracellular domain of HER2 (ERBB2); blocks HER2-driven signaling and proliferation, promotes receptor downregulation, and engages Fcγ receptor–bearing effector cells to mediate antibody-dependent cellular cytotoxicity (ADCC) against HER2-overexpressing tumor cells.
YES
DIRECT
Trastuzumab binds HER2 on tumor cells and engages Fcγ receptor–bearing immune cells (e.g., NK cells, macrophages) to mediate antibody‑dependent cellular cytotoxicity; it also inhibits HER2 signaling, promoting apoptosis.
Type II, glycoengineered anti-CD20 IgG1 monoclonal antibody that depletes CD20+ B cells via ADCC/ADCP and direct cell death, reducing anti-PLA2R autoantibodies.
Type II, glycoengineered anti-CD20 IgG1 that binds CD20 on B cells and depletes CD20+ B cells via enhanced Fc gamma RIII–mediated ADCC/ADCP and direct cell death, reducing pathogenic anti-PLA2R autoantibodies.
YES
DIRECT
Obinutuzumab binds CD20 on B cells; its glycoengineered Fc engages FcγRIIIa to trigger NK-cell ADCC and macrophage ADCP, and CD20 ligation induces direct caspase-independent cell death (limited CDC).
Type II, glycoengineered anti-CD20 IgG1 monoclonal antibody that depletes CD20+ B cells via ADCC/ADCP and direct cell death, reducing anti-PLA2R autoantibodies.
Type II, glycoengineered anti-CD20 IgG1 that binds CD20 on B cells and depletes CD20+ B cells via enhanced Fc gamma RIII–mediated ADCC/ADCP and direct cell death, reducing pathogenic anti-PLA2R autoantibodies.
NO
INDIRECT
Obinutuzumab binds CD20 on B cells; its Fc engages FcγRIIIa (CD16a) on NK cells/macrophages to mediate ADCC/ADCP against CD20+ cells. CD16a-expressing effector cells are not targeted or killed by the drug.
Rabbit polyclonal anti-thymocyte globulin that depletes T cells to prevent rejection and GVHD.
Rabbit polyclonal anti-thymocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, producing immunosuppression to prevent rejection and GVHD.
YES
DIRECT
Polyclonal antibodies in ATG bind CD18 on T cells, triggering complement-dependent lysis, antibody-dependent cellular cytotoxicity, and apoptosis to deplete target-expressing cells.